Search

Your search keyword '"Zinzani, Pier L."' showing total 6 results
Start Over Author "Zinzani, Pier L." Topic business.industry
6 results on '"Zinzani, Pier L."'

1. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma

Author

Connors, Joseph M, Jurczak, Wojciech, Straus, David J, Ansell, Stephen M, Kim, Won S, Gallamini, Andrea, Younes, Anas, Alekseev, Sergey, Illés, Árpád, Picardi, Marco, Lech-Maranda, Ewa, Oki, Yasuhiro, Feldman, Tatyana, Smolewski, Piotr, Savage, Kerry J, Bartlett, Nancy L, Walewski, Jan, Chen, Robert, Ramchandren, Radhakrishnan, Zinzani, Pier L, Cunningham, David, Rosta, Andras, Josephson, Neil C, Song, Eric, Sachs, Jessica, Liu, Rachael, Jolin, Hina A, Huebner, Dirk, Radford, John, Luminari, Stefano, DIPARTIMENTO DI MEDICINA SPECIALISTICA, DIAGNOSTICA E SPERIMENTALE, Connors, J. M., Jurczak, W., Straus, D. J., Ansell, S. M., Kim, W. S., Gallamini, A., Younes, A., Alekseev, S., Illés, A., Picardi, M., Lech-Maranda, E., Oki, Y., Feldman, T., Smolewski, P., Savage, K. J., Bartlett, N. L., Walewski, J., Chen, R., Ramchandren, R., Zinzani, P. L., Cunningham, D., Rosta, A., Josephson, N. C., Song, E., Sachs, J., Liu, R., Jolin, H. A., Huebner, D., and Radford, J.

Subjects
Male, Oncology, medicine.medical_treatment, chemistry.chemical_compound, Immunologic Factor, 0302 clinical medicine, Brentuximab vedotin, anti-CD30, Brentuximab vedotin, Aged, 80 and over, Medicine (all), Orvostudományok, General Medicine, Middle Aged, Hodgkin Disease, Vinblastine, Dacarbazine, Survival Rate, 030220 oncology & carcinogenesis, Female, Human, medicine.drug, Adult, medicine.medical_specialty, Neutropenia, Adolescent, Klinikai orvostudományok, Bleomycin, Disease-Free Survival, Article, Follow-Up Studie, Young Adult, 03 medical and health sciences, Internal medicine, medicine, anti-CD30, Survival rate, Aged, Neoplasm Staging, Chemotherapy, Antineoplastic Combined Chemotherapy Protocol, business.industry, Hodgkin's lymphoma, medicine.disease, Immunoconjugate, chemistry, ABVD, Doxorubicin, business, 030215 immunology
Abstract

none 29 si This article was published on December 10, 2017. All ECHELON-1 investigators are listed in the Supplementary Appendix, available at NEJM.org Background Brentuximab vedotin is an anti-CD30 antibody-drug conjugate that has been approved for relapsed and refractory Hodgkin's lymphoma. Methods We conducted an open-label, multicenter, randomized phase 3 trial involving patients with previously untreated stage III or IV classic Hodgkin's lymphoma, in which 664 were assigned to receive brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) and 670 were assigned to receive doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). The primary end point was modified progression-free survival (the time to progression, death, or noncomplete response and use of subsequent anticancer therapy) as adjudicated by an independent review committee. The key secondary end point was overall survival. Results At a median follow-up of 24.9 months, 2-year modified progression-free survival rates in the A+AVD and ABVD groups were 82.1% (95% confidence interval [CI], 78.7 to 85.0) and 77.2% (95% CI, 73.7 to 80.4), respectively, a difference of 4.9 percentage points (hazard ratio for an event of progression, death, or modified progression, 0.77; 95% CI, 0.60 to 0.98; P=0.03). There were 28 deaths with A+AVD and 39 with ABVD (hazard ratio for interim overall survival, 0.72 [95% CI, 0.44 to 1.17]; P=0.19). All secondary efficacy end points trended in favor of A+AVD. Neutropenia occurred in 58% of the patients receiving A+AVD and in 45% of those receiving ABVD; in the A+AVD group, the rate of febrile neutropenia was lower among the 83 patients who received primary prophylaxis with granulocyte colony-stimulating factor than among those who did not (11% vs. 21%). Peripheral neuropathy occurred in 67% of patients in the A+AVD group and in 43% of patients in the ABVD group; 67% of patients in the A+AVD group who had peripheral neuropathy had resolution or improvement at the last follow-up visit. Pulmonary toxicity of grade 3 or higher was reported in less than 1% of patients receiving A+AVD and in 3% of those receiving ABVD. Among the deaths that occurred during treatment, 7 of 9 in the A+AVD group were associated with neutropenia and 11 of 13 in the ABVD group were associated with pulmonary-related toxicity. Conclusions A+AVD had superior efficacy to ABVD in the treatment of patients with advanced-stage Hodgkin's lymphoma, with a 4.9 percentage-point lower combined risk of progression, death, or noncomplete response and of subsequent anticancer therapy at 2 years. (Funded by Millennium Pharmaceuticals and Seattle Genetics; ECHELON-1 ClinicalTrials.gov number, NCT01712490 ; EudraCT number, 2011-005450-60 .). mixed Joseph M. Connors; Wojciech Jurczak; David J. Straus; Stephen M. Ansell; Won S. Kim; Andrea Gallamini; Anas Younes; Sergey Alekseev; Árpád Illés; Marco Picardi; Ewa Lech-Maranda; Yasuhiro Oki; Tatyana Feldman; Piotr Smolewski; Kerry J. Savage; Nancy L. Bartlett; Jan Walewski; Robert Chen; Radhakrishnan Ramchandren; Pier L. Zinzani; David Cunningham; Andras Rosta; Neil C. Josephson; Eric Song; Jessica Sachs; Rachael Liu; Hina A. Jolin; Dirk Huebner; John Radford for the ECHELON-1 Study Group Joseph M. Connors; Wojciech Jurczak; David J. Straus; Stephen M. Ansell; Won S. Kim; Andrea Gallamini; Anas Younes; Sergey Alekseev; Árpád Illés; Marco Picardi; Ewa Lech-Maranda; Yasuhiro Oki; Tatyana Feldman; Piotr Smolewski; Kerry J. Savage; Nancy L. Bartlett; Jan Walewski; Robert Chen; Radhakrishnan Ramchandren; Pier L. Zinzani; David Cunningham; Andras Rosta; Neil C. Josephson; Eric Song; Jessica Sachs; Rachael Liu; Hina A. Jolin; Dirk Huebner; John Radford for the ECHELON-1 Study Group

Published
2018

2. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia

Author

Awan, Farrukh T, Hillmen, Peter, Hellmann, Andrzej, Robak, Tadeusz, Hughes, Steven G., Trone, Denise, Shannon, Megan, Flinn, Ian W., Byrd, John C., Riveros, Dardo, Pavlovsky, Santiago, Iastrebner, Claudio M., Carney, Dennis A., Deveridge, Sandra, Durrant, Simon, Hahn, Uwe H., Hertzberg, Mark, Leahy, Michael F., David, Ma, Marlton, Paula, Mulligan, Stephen, Opat, Stephen S., Tiley, Campbell, Wickham, Nicholas W., Cannell, Paul, Gatalano, John, Catalano, John, Cull, Gavin, Luen B., To, Hopfinger, Georg, Jager, Ulrich, Linkesch, Werner, Petzer, Andreas, Schwarzmeier, Josef, Steurer, Michael, Greil, Richard, Bememan, Zwi, Bosly, Andre, Bron, Dominique, Janssens, Ann, Offner, Fritz, Van Den Neste, Eric W., Ka Lung, Wu, Van Hoof, Achiel, Maiolino, Angelo, Pinczowski, Helio, Zanichelli, Maria A., Pereira, Juliana, Larratt, Loree, Spaner, David, Howson Jan, Kang, Chen, Christine I., Cantin, Guy, Fernandez, Louis A., Fraser, Graeme, Mayer, Jiri, Trneny, Marek, Jebavy, Ladislav, Bordessoule, Dominique, Lamy, Thierry, Milpied, Noel, Truchan Graczyk, Malgorzata, Eghbali, Houchingue, Karsenti, Jean Michel, Celigny, Philippe Solal, Mans, Le, Cazin, Bruno, Gyan, Emmanuel, Lepretre, Stephane, Bergmann, Lothar, Tsionos, Konstantinos, Lokeshwar, Nilesh M., Agarwal, Mohan B., Ross, Cecil R., Deshmukh, Chetan D., Narayanan, Geetha, Raina, Vinod, Bondarde, Shailesh A., Shah, Bhavin A., Bairey, Osnat, Tikva, Petach, Shvidel, Lev, Ambrosetti, Achille, Rossi, Policlinico G. B., Angelucci, Emanuele, Carella, Angelo M., Massaia, Massimo, Zinzani, Pier L., Caligaris Cappio, Federico, Foa, Roberto, Gaidano, Gianluca, della Caritá, A. O. Maggiore, Leone, Giuseppe, Santoro, Armando, Griskevicius, Laimonas, Jurgutis, Romualdas, Baker, Bartrum W., Hawkins, Timothy, Corbett, Gillian M., Ganly, Peter, D'Souza, Alvyn B., Deptala, Andrzej, Holowiecki, Jerzy, Kloczko, Janusz, Skotnicki, Aleksander, Zdziarska, Barbara, Kyrcz Krzemien, Slawomira, Dmoszynska, Anna, Moreira, Anna, Pereira, Ana P., Colita, Andrei, Moicean, Andreea D., Vasilica, Mariana, Danaila, Catalin, Gheorghita, Emanuil, Pavlov, Vyacheslav V., Rossiev, Viktor A., Konstantinova, Tatiana, Samoilova, Olga S., Novgorod, Nizhniy, Shelekhova, Tatyana, Zaritsky, Andrey Y., Abdulkadyrov, Kudrat M., Zyuzgin, Ilya S., Pristupa, Alexander S., Loscertales, Javier, Vidal, Joan Besalduch, de Mallorca, Palma, Gonzalez, Marcos, Ortuno, Francisco, Giraldo, Pilar, Nathwani, Amit, Agrawal, Samir G., Rule, Simon, Dearden, Claire E., Bloor, Adrian J., Haynes, Andrew, Singer, Charles, Boclek, Robert G., Bosserman, Linda D., Chan, David, Davidson, Sheldon J., Dichmann, Robert A., Farber, Charles, Hart, Lowell, Hermann, Robert, Eddie, Hu, Janakiraman, Nalini, Jonas, William, Liem, Kiem D., Mcintyre, Rosemary E., O'Brien, Susan, Patel, Giribala, Rado, Thomas, Schilder, Russell, Smith, Scott E., Stock, Wendy, Turturro, Francesco, Venugopal, Parameswaran, Anderson, Thomas C., Berry, William, Boyd, Thomas E., Byrd, John, Cooper, Maureen, Flinn, Ian, Gersh, Robert, Gordon, David, Guzley, Gregory J., Wilks, Sharon T., Klein, Andreas, Krauss, John C., Lister, John, Mandell, Lance, Molina, Arthur, Cooper, Barry, Pendergrass, Kelly B., Reeder, Craig, Savin, Michael A., Spitzer, Gary, Tuscano, Joseph M., Vandeventer, Hendrik, Eradat, Herbert A., Masood, Aisha, Mena, Raul, F. T. Awan, P. Hillmen, A. Hellmann, T. Robak, S. G. Hughe, D. Trone, M. Shannon, I. W. Flinn, J. C. Byrd, L. U. C., and Riveros D, Iastrebner CM, Carney DA, Deveridge S, Durrant S, Hahn UH, Hertzberg M, Leahy MF, Ma D, Marlton P, Mulligan S, Opat SS, Tiley C, Wickham NW, Cannell P, Gatalano J, Cull G, B To L, Catalano J, Wickham NW, Hopfinger G, Jager U, Linkesch W, Petzer A, Schwarzmeier J, Steurer M, Greil R, Bememan Z, Bosly A, Bron D, Janssens A, Offner F, Van Den Neste EW, Wu KL, Van Hoof A, Maiolino A, Pinczowski H, Zanichelli MA, Pereira J, Larratt L, Spaner D, Howson-Jan K, Chen CI, Fernandez LA, Fraser G, Mayer J, Trneny M, Jebavy L, Bordessoule D, Lamy T, Milpied N, Eghbali H, Karsenti JM, Celigny PS, Cazin B, Gyan E, Lepretre S, Bergmann L, Tsionos K, Lokeshwar NM, Agarwal MB, Ross CR, Deshmukh CD, Narayanan G, Raina V, Bondarde SA, Shah BA, Bairey O, Ben-Yehuda D, Shvidel L, Ambrosetti A, Angelucci E, Carella AM, Massaia M, Zinzani PL, Caligaris-Cappio F, Foa R, Gaidano G, Leone G, Santoro A, Griskevicius L, Jurgutis R, Baker BW, Hawkins T, Corbett GM, Ganly P, D'Souza AB, Deptala A, Hellmann A, Holowiecki J, Kloczko J, Skotnicki A, Zdziarska B, Robak T, Dmoszynska A, Moreira I, Pereira AP, Colita A, Moicean AD, Gheorghita E, Vasilica M, Pavlov VV, Rossiev VA, Konstantinova T, Samoilova OS, Novgorod N, Shelekhova T, Zaritsky AY, Abdulkadyrov KM, Zyuzgin IS, Pristupa AS, Loscertales J, Casado LF, Gonzalez M, Ortuno F, Giraldo P, Servet M, Nathwani A, Howson-Jan K, Agrawal SG, Hillmen P, Rule S, Dearden CE, Bloor AJ, Haynes A, Singer C, Boclek RG, Bosserman LD, Chan D, Davidson SJ, Dichmann RA, Farber C, Guzley GJ, Hermann R, Hu E, Janakiraman N, Jonas W, Liem KD, Mcintyre RE, O'Brien S, Patel G, Rado T, Schilder R, Smith SE, Stock W, Turturro F, Venugopal P, Berry W, Boyd TE, Byrd J, Cooper M, Flinn I, Gersh R, Gordon D, Wilks ST, Klein A, Krauss JC, Lister J, Mandell L, Molina A, Pendergrass KB, Reeder C, Savin MA, Spitzer G, Tuscano JM, van Deventer H, Eradat HA, Cooper B, Masood A, Mena R.

Subjects
Oncology, Male, Chronic lymphocytic leukaemia, Vascular damage Radboud Institute for Health Sciences [Radboudumc 16], Pharmacology, Antibodies, Monoclonal, Murine-Derived, Recurrence, hemic and lymphatic diseases, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Medicine, drug therapy, Male, Middle Aged, Recurrence, Vidarabine, Chronic, Aged, 80 and over, Leukemia, Medicine (all), Antibodies, Monoclonal, Hematology, Middle Aged, Adult, Aged, Aged, Lymphocytic, Fludarabine, Tolerability, Small lymphocytic lymphoma, administration /&/ dosage/adverse effects, Female, Humans, Leukemia, Rituximab, Female, Vidarabine, medicine.drug, Adult, Murine-Derived, medicine.medical_specialty, Cyclophosphamide, chemical and pharmacologic phenomena, CD23, Lumiliximab, Aged, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Antibodies, chronic lymphocytic leukaemia, lumiliximab, small lymphocytic lymphoma, Internal medicine, administration /&/ dosage/adverse effects/analogs /&/ derivatives, 80 and over, Antibodie, Adverse effect, Lymphocytic leukaemia, business.industry, administration /&/ dosage/adverse effects, Antibodie, B-Cell, administration /&/ dosage/adverse effects, Cyclophosphamide, Interim analysis, administration /&/ dosage/adverse effects, Antineoplastic Combined Chemotherapy Protocol, business
Abstract

Item does not contain fulltext Lumiliximab is a chimeric monoclonal antibody that targets CD23 on the surface of chronic lymphocytic leukaemia (CLL) B-cells. Early phase clinical studies with lumiliximab alone and in combination with fludarabine, cyclophosphamide and rituximab (FCR) established its potential efficacy and tolerability. The 152CL201 trial [Lumiliximab with fludarabine, cyclophosphamide and rituximab (FCR) versus FCR alone in subjects with relapsed CLL; LUCID] was a phase 2/3, randomized (1:1), open-label, multicentre study of lumiliximab in combination with FCR versus FCR alone in patients with relapsed CLL. Six hundred and twenty-seven patients were randomized to either arm. Overall the combination of lumiliximab with FCR was not significantly better than FCR alone (overall response rate 71% vs. 72%, complete response rate 16% vs. 15%, median progression-free survival 24.6 vs. 23.9 months respectively, for FCR with and without lumiliximab). There was a slightly increased incidence of adverse events with lumiliximab but these increases did not appear to lead to differences in eventual outcomes. An interim analysis failed to show sufficient efficacy of the combination of lumiliximab with FCR. The study was therefore stopped early for lack of efficacy. Despite the eventual outcome, the LUCID trial is one of the largest studies that provides valuable insight into the efficacy and tolerability of FCR as a therapeutic option for patients with relapsed CLL.

Published
2014

3. (90) Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) - The Zeno Study

Author

Michele Cavo, Ginevra Lolli, Matteo Carella, Vittorio Stefoni, Alessandro Broccoli, Cinzia Pellegrini, Pier Luigi Zinzani, Alice Morigi, Miriam Marangon, Laura Nanni, Lisa Argnani, Beatrice Casadei, Lolli, Ginevra, Argnani, Lisa, Broccoli, Alessandro, Marangon, Miriam, Pellegrini, Cinzia, Morigi, Alice, Casadei, Beatrice, Nanni, Laura, Stefoni, Vittorio, Carella, Matteo, Cavo, Michele, and Zinzani, Pier L

Subjects
business.industry, treatment-naïve, Ibritumomab tiuxetan, 90Y-ibritumomab tiuxetan, MALT lymphoma, Hematology, medicine.disease, extra-nodal marginal zone B-cell lymphoma, Therapy naive, relapsed, Cancer research, medicine, 90Y ibritumomab tiuxetan, In patient, Extra nodal, Marginal zone B-cell lymphoma, business, Mucosa-associated lymphoid tissue, medicine.drug
Abstract

No abstract available.

Published
2020

4. Granulomatous tattoo reaction in a nivolumab-treated patient

Author

Pier Luigi Zinzani, Alessandro Pileri, Michela Starace, Alice Morigi, Claudio Agostinelli, Miriam Leuzzi, Annalisa Patrizi, Elena Sabattini, Pileri, Alessandro, Starace, Michela, Leuzzi, Miriam, Agostinelli, Claudio, Sabattini, Elena, Morigi, Alice, Zinzani, Pier L, and Patrizi, Annalisa

Subjects
Treated patient, medicine.medical_specialty, Text mining, Nivolumab, business.industry, medicine, MEDLINE, Dermatology, business
Abstract

N/A N/A

Published
2020

5. Radioimmunotherapy as the first line of treatment in non-Hodgkin lymphoma

Author

Mahsa Eskian, MirHojjat Khorasanizadeh, Pier Luigi Zinzani, Nima Rezaei, Eskian, Mahsa, Khorasanizadeh, MirHojjat, Zinzani, Pier L, and Rezaei, Nima

Subjects
Oncology, medicine.medical_specialty, medicine.medical_treatment, First line, Immunology, first line, Maintenance Chemotherapy, 03 medical and health sciences, 0302 clinical medicine, rituximab, immune system diseases, Internal medicine, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Immunology and Allergy, Survival rate, induction, Chemotherapy, business.industry, Lymphoma, Non-Hodgkin, Antibodies, Monoclonal, Induction Chemotherapy, Immunotherapy, medicine.disease, Lymphoma, Consolidation Chemotherapy, Radiation therapy, Treatment Outcome, 030220 oncology & carcinogenesis, Radioimmunotherapy, radioimmunotherapy, Rituximab, business, consolidation, 030215 immunology, medicine.drug
Abstract

Non-Hodgkin lymphoma (NHL) is the most common hematologic malignancy. The estimated deaths and new cases of NHL in the USA in 2018 have reached 19,910 and 74,680, respectively, with 5-year survival rate of 71%. Therapeutic interventions for NHL consist of chemotherapy, radiation therapy and immunotherapy. Radioimmunotherapy (RIT) is a potential alternative treatment for NHL that is currently used in different lines of treatment. Studies show that nuclear medicine physicians and radiation oncologists are not yet certain about the proper line for administration of RIT. Herein, we have reviewed the efficiency and toxicity of RIT as the first line of treatment, and discussed potential novel indications, and strategies such as modifying induction therapy and using rituximab maintenance to optimize the efficiency of RIT as the first line of treatment. Our review indicates that it is more logical to postpone conventional therapies to the second or third lines of treatment instead of RIT.

Published
2018

6. Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study

Author

Luigi Rigacci, Maurizio Martelli, Luca Ceriani, Manuel Gotti, Luca Giovanella, Caterina Stelitano, Pier Luigi Zinzani, Emanuele Zucca, Andrés J.M. Ferreri, Annarita Conconi, Barbara Botto, Maria Giuseppina Cabras, Peter Johnson, Ceriani, Luca, Martelli, Maurizio, Conconi, Annarita, Zinzani, Pier L, Ferreri, Andrés J M, Botto, Barbara, Stelitano, Caterina, Gotti, Manuel, Cabras, Maria G, Rigacci, Luigi, Giovanella, Luca, Zucca, Emanuele, and Johnson, Peter W M

Subjects
0301 basic medicine, Adult, Male, medicine.medical_specialty, Kaplan-Meier Estimate, Total lesion glycolysis, Prognostic factors, Mediastinal Neoplasms, 03 medical and health sciences, 0302 clinical medicine, Fluorodeoxyglucose F18, Predictive Value of Tests, Positron Emission Tomography Computed Tomography, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, B-cell lymphoma, prognostic factor, Primary mediastinal B-cell lymphoma, Prognostic models, Positron-emission tomography, Positron-emission tomography metrics, Hematology, medicine.diagnostic_test, business.industry, medicine.disease, Prognosis, Lymphoma, 030104 developmental biology, Positron emission tomography, positron-emission tomography metric, 030220 oncology & carcinogenesis, Extranodal lymphoma, Fdg pet ct, Female, Radiology, Lymphoma, Large B-Cell, Diffuse, Radiopharmaceuticals, business, Glycolysis
Abstract

The International Extranodal Lymphoma Study Group-26 study evaluated the prognostic role of 18-fluorodeoxyglucose positron-emission tomography (PET) in primary mediastinal large B-cell lymphoma. We assessed quantitative PET parameters at diagnosis and post-treatment in 100 patients. The end-of-therapy total lesion glycolysis (TLG) was the best individual outcome predictor, but the combination of baseline TLG and end-of-therapy visual analysis with Deauville Score (DS) showed a better positive predictive value. A model in which baseline TLG is combined with interim DS might identify patients with shorter progression-free survival. PET metrics combined with interim DS may allow early risk assessment and warrants further studies.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results